AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Dow obtains patents for production of glycoproteins in plant systems.(Brief Article)
2002 NOV 13 - (NewsRx.com & NewsRx.net) -- The Dow Chemical Company (NYSE:DOW) has acquired a global, exclusive assignment of patents involving significant technology in protein glycosylation for enabling the production of "mammalian-like" glycans in plants.
Many protein-based therapeutics require glycosyl groups for full functionality. To date, the dominant production method for preparing glycoproteins has involved mammalian cell cultures. The patents acquired by Dow were obtained from inventors Dr. Tatsuji Seki and Dr. Kazuhito Fujiyama, based on work completed while working at the University of Osaka, Japan.
According to Kurt Hoeprich of Dow, the company views the glycosylation technology involved in these patents as a significant event in the field of biopharmaceutical production using a plant-based approach.
By enabling the production of mammalian-like glycan structures, the new technology can potentially equip the plant-based approach to help overcome the high capital costs and production capacity limitations of current manufacturing ...
- Dow Obtains Patents for Production of Glycoproteins In Transgenic Plant Systems.
- Press release article from: PR Newswire October 1, 2002 700+ words
SAN DIEGO -- The Dow Chemical Company has acquired a global...cell cultures. The patents acquired by Dow were obtained from inventors Dr. Tatsuji...Hoeprich, Director of Market Development for Dow Plant- Based Biopharmaceuticals, Dow views...
- Dow obtains patents for production of glycoproteins in plant systems.
- Newspaper article from: Biotech Week November 13, 2002 700+ words
...13 - (NewsRx.com & NewsRx.net) -- The Dow Chemical Company (NYSE:DOW) has acquired a global, exclusive assignment of...mammalian cell cultures. The patents acquired by Dow were obtained from inventors Dr. Tatsuji Seki and...
- Symantec obtains patents on microdefinition system.(Company Business and...
- Newspaper article from: Telecomworldwire February 9, 2001 700+ words
TELECOMWORLDWIRE-9 February 2001-Symantec obtains patents on microdefinition system (C)1994-2001 M2 COMMUNICATIONS LTD http://www.m2.com Symantec Corp has received two new...
- Pfafftown, N.C., pair invents products and obtains patents for them.
- Newspaper article from: Knight Ridder/Tribune Business News June 23, 2004 700+ words
...partners own Brooks & Baker LLC, formerly Baker Innovations LLC, a company in Pfafftown that develops products and obtains patents for them. "It's not cheap," said Baker, who has been inventing products since 1989. "I'll be the first to say...
- Rhodia.(obtains patents)(Brief Article)
- Magazine article from: Soap & Cosmetics September 1, 1999 700+ words
Using gemini surfactants, Rhodia has devised a composition that provides enhanced soil release, which may be useful in surfactant additive packages, detergents and fabric softeners. The subject of patent #5,922,663, the composition includes: a conventional surfactant comprised of a hydrophilic
- Prometheus Obtains Patents for Thiopurine Metabolite Testing.
- Newspaper article from: BIOTECH Patent News October 1, 2008 700+ words
Prometheus Laboratories, Inc. (San Diego, CA), a specialty pharmaceutical and diagnostics company, announced that the United States Patent and Trademark Office issued two separate patents covering the technology for PROMETHEUS Thiopurine Metabolites, a diagnostic test that enables physicians to
- Sequenom Obtains Patents for DNA MassArray Technology.
- Press release article from: Business Wire April 27, 1999 700+ words
SAN DIEGOBW HealthWireApril 27, 1999-- Sequenom, Inc. today announced that it has obtained two patents from the U.S. Patent and Trademark Office (#5,872,003 & #5,851,765) entitled "DNA Sequencing by Mass Spectrometry Via Exonuclease Degradation," expanding the company's patent estate for its
- Sirna Therapeutics obtains patents covering siRNAs targeting VEGF and HCV.
- Newspaper article from: BIOTECH Patent News June 1, 2005 700+ words
Sirna Therapeutics, Inc. (Boulder, CO) announced that the United Kingdom Patent Office has granted the company two additional short interfering RNA (siRNA) target patents. The first patent covers any siRNA with one or more chemical modifications targeting Vascular Endothelial Growth Factor (VEGF).